U.S. Markets open in 5 hrs 36 mins

Voyager Shares Take Off on Parkinson's Disease Development Deal

M. Corey Goldman

surged more than 20% on Friday after the gene therapy company announced a collaboration agreement with pharmaceutical giant AbbVie Inc. Under terms of the agreement, Voyager will receive $65 million upfront and up to $245 million in preclinical and phase 1 option payments, as well as up to an additional $728 million in potential development, regulatory, and commercial milestone payments and royalties. LATEST NEWS: We just announced a new collaboration w/ @VoyagerTx focused on developing potential treatments for Parkinson's disease.